However, we found a significantly different concentration of mean ADMA between subtypes of breast cancer patients (p for trend = 0.040; Fig. 1); namely patients with triple-negative cancer had the highest mean ADMA concentration, whilst mean ADMA was lowest in HER2-positive patients. This evidence concerns the gene ERBB2 and breast carcinoma.